Compass Capital Management Inc. Has $7.87 Million Stock Holdings in Zoetis Inc. $ZTS

Compass Capital Management Inc. lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 28.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,582 shares of the company’s stock after acquiring an additional 13,734 shares during the quarter. Compass Capital Management Inc.’s holdings in Zoetis were worth $7,874,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. RFG Advisory LLC boosted its holdings in shares of Zoetis by 4.9% during the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after acquiring an additional 80 shares in the last quarter. YANKCOM Partnership boosted its holdings in shares of Zoetis by 3.5% during the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock valued at $302,000 after acquiring an additional 81 shares in the last quarter. Beese Fulmer Investment Management Inc. boosted its holdings in shares of Zoetis by 2.4% during the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock valued at $537,000 after acquiring an additional 85 shares in the last quarter. Quest 10 Wealth Builders Inc. boosted its holdings in shares of Zoetis by 4.7% during the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock valued at $240,000 after acquiring an additional 86 shares in the last quarter. Finally, Financial Engines Advisors L.L.C. boosted its holdings in shares of Zoetis by 4.4% during the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock valued at $299,000 after acquiring an additional 87 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. UBS Group cut their price objective on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Stifel Nicolaus cut their price objective on Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a report on Friday, May 22nd. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Bank of America raised their price objective on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. Finally, Morgan Stanley reissued an “overweight” rating and set a $115.00 price objective on shares of Zoetis in a report on Friday, May 15th. Six equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $133.92.

Insiders Place Their Bets

In other news, Director Paul Bisaro purchased 2,000 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were acquired at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the acquisition, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction on Monday, May 11th. The stock was purchased at an average cost of $77.76 per share, with a total value of $233,280.00. Following the purchase, the director directly owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 11,650 shares of company stock worth $886,384. Corporate insiders own 0.22% of the company’s stock.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms, including Rosen, Bronstein Gewirtz & Grossman, the Schall Law Firm, DJS Law Group, and others, urged investors to join or lead a class action against Zoetis, keeping litigation risk in focus and potentially weighing on sentiment. Article Title
• Negative Sentiment: The lawsuits allege Zoetis misled investors about weakening veterinarian adoption and prescription trends, which could raise concerns about the company’s underlying growth outlook and create overhang on the stock. Article Title
• Neutral Sentiment: Rosen Law Firm and others reminded shareholders that July 27, 2026 is the lead-plaintiff deadline, but these notices are procedural and do not change Zoetis’ fundamentals by themselves. Article Title
• Neutral Sentiment: Bank of America Securities reportedly maintained a “Hold” rating on Zoetis, which suggests Wall Street remains cautious but not overtly bearish. Article Title

Zoetis Stock Performance

ZTS stock opened at $81.51 on Friday. The stock has a 50-day moving average price of $97.70 and a 200-day moving average price of $114.47. Zoetis Inc. has a 1-year low of $72.38 and a 1-year high of $168.83. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The firm has a market cap of $34.17 billion, a PE ratio of 13.52, a price-to-earnings-growth ratio of 1.27 and a beta of 0.75.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same period last year, the business posted $1.48 earnings per share. The business’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities research analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.